Possible pathway for formation of fibrin degradation products during ancrod therapy.
D000721:Ancrod / Q000494:pharmacology / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000097:blood / Q000188:drug therapy*; D010450:Endopeptidases / Q000627:therapeutic use*; D005337:Fibrin / Q000378:metabolism*; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D012995:Solubility; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy*
D005337:Fibrin; D005340:Fibrinogen; D010450:Endopeptidases; D000721:Ancrod